avantiavanti schreef op 21 februari 2020 06:12:
Barclays 20 februari 2020
FY19 first take: not too much in the financials in its last pre-commercial year
Stock Rating/Industry View: Overweight/Positive
Price Target: EUR 225.00
Price (20-Feb-2020): EUR 242.70
Potential Upside/Downside: -7%
Tickers: GLPG NA / GLPG.AS
....
The YTD strength in GLPG shares has been a high topic of investor inquiries really since 4Q19 began (see: Christmas comes early for GLPG holders - thoughts on the recent outperformance (13/12/19). Whilst we can’t point to any one reason for the strong performance of shares, the message from the company continues to pitch 2020 as a catalyst-rich year (see: European Mid Cap Pharmaceuticals: Thoughts into 4Q19 earnings: No signs of this bull getting the horns (20/01/20)), with the next catalyst likely being the FDA acceptance of the filgotinib filing, which should he happening any day now.
.....